Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Cloud-Based vs. In-House Electronic Health Records

Health organizations have been leveraging technology for some time to improve patient experiences and make workflows more efficient, and the central hub for clinicians to record, store and share data is their EHR. Many factors need to be considered when choosing the right EHR, including whether it’s cloud-based or on-site. The biggest difference between the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Health organizations have been leveraging technology for some time to improve patient experiences and make workflows more efficient, and the central hub for clinicians to record, store and share data is their EHR.

Many factors need to be considered when choosing the right EHR, including whether it’s cloud-based or on-site. The biggest difference between the two is where the data lives. In cloud-based EHRs, patient records live in an internet-based, on-demand network. On-premise EHRs require data to be hosted locally and housed on-site, which requires significant hardware investment.

So, which is right for your organization?

Cloud-Based EHRs Offer Many Advantages

The cloud has become a vital tool in how organizations use technology, and it provides many benefits for those who adopt it. Cloud-based EHRs are relatively popular, and a study from HIMSS revealed that about two-thirds of healthcare organizations use the cloud or cloud services. So, why have so many migrated to cloud-based EHRs?

The cloud presents multiple opportunities for healthcare entities to reduce costs, enhance security and improve interoperability.

Reduce Costs and Capital Investment

Setting up a new EHR can require substantial capital depending on your requirements, especially if you are responsible for hardware and upgrades. With a cloud-based EHR, you’ll reduce costs associated with EHR implementation, management, and storage.

Every time a new upgrade occurs, you won’t incur additional costs to enhance your servers. With the cloud, you are only paying for the storage that you need, and you don’t need additional IT resources.

Enhance Data Security

Keeping healthcare data safe is paramount and required by HIPAA and other privacy regulations. Moving to the cloud improves the security of your data. Cloud service providers deliver highly secure and well-protected data centers that easily thwart cyberattacks, mostly through tactics like encryption.

Having an on-site server means you are completely responsible for its security, which may be a hard task to ensure, especially for small healthcare entities that don’t have the resources.

Improve Interoperability for Better Patient Outcomes

The world of healthcare data places substantial emphasis on that the ability to share that data across applications. Healthcare interoperability is critical in the modern world, enabling greater access to information to improve patient care.

This data sharing must be secure and seamless, which is better accomplished by using the cloud. Interoperability boosts clinician satisfaction with EHRs, which is much harder to execute with on-premise EHRs.

On-premise applications suffer from poor usability, hampering the ability to exchange data. Cloud-based applications can be a huge help in overcoming interoperability barriers, which, in turn, improves patient outcomes.

Your EHR Should Deliver Advantages, Not Obstacles

Your EHR solution is one of your most valuable tools. Being stuck with on-premise systems is keeping you from realizing multiple benefits.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512